Caligan Partners LP

Caligan Partners LP is an Investment Adviser institutional filer with the SEC under CIK 1727492, reporting 25 portfolio positions, with 20 historical 13F filings on file. Most recent reporting period: 2026-06-30.

A Form 13F reports a manager's US-listed stock and option positions only. It does not include real estate, private funds, bonds, cash or non-US holdings, so a 13F portfolio value is not the firm's total assets under management (AUM).

• State of incorporation: DE
• Filing type: 13F-HR
• Latest reporting period: 2026-06-30
• Last filed: 2026-08-14

Top 10 portfolio positions

The largest reported holdings in Caligan Partners LP's most recent 13F filing, ranked by reported market value.

1. LIQUIDIA CORPORATION (LQDA)
2. REVOLUTION MEDICINES INC (RVMD)
3. ABIVAX SA (ABVX)
4. VAXCYTE INC (PCVX)
5. EXELIXIS INC (EXEL)
6. TANGO THERAPEUTICS INC (TNGX)
7. AVALO THERAPEUTICS INC (AVTX)
8. XENON PHARMACEUTICALS INC (XENE)
9. ADMA BIOLOGICS INC (ADMA)
10. LB PHARMACEUTICALS INC (LBRX)